plasminogen sold brand name ryplazim biologic medication treatment hypoplasminogenemia plasminogen deficiency type purified human administered common side effects include abdominal pain bloating nausea bleeding limb pain fatigue constipation dry mouth headache dizziness joint pain back individuals hypoplasminogenemia lack protein called plasminogen responsible ability body break fibrin plasminogen deficiency leads accumulation fibrin causing development growths lesions impair normal tissue organ function may lead blindness lesions affect plasminogen humantvmh approved medical use united states june first therapy hypoplasminogenemia approved us food drug administration plasminogen humantvmh indicated treatment people plasminogen deficiency type also referred hypoplasminogenemia disorder impair normal tissue organ function may lead effectiveness safety plasminogen primarily based one singlearm openlabel unblinded clinical trial enrolling adult pediatric participants plasminogen deficiency type participants received plasminogen administered every two four days effectiveness plasminogen demonstrated least improvement lesions participants lesions baseline absence recurrent new lesions participants weeks us food drug administration fda granted application plasminogen orphan drug fast track designation priority review rare pediatric disease priority review fda granted approval ryplazim prometic biotherapeutics article incorporates public domain material united states department health human services drug article relating blood blood forming organs stub help wikipedia expanding